Company: LNAI
Filing Date: 2025-12-03
Form Type: 424B5
Source: 0001731122-25-001626
Chunk: 1

Company: Lunai Bioworks Inc.
Filing Date: 2025-12-03
Form: 424B5
Chunk 1
---
. In connection with the sale
of the Common Stock on our behalf, Dawson James will be deemed to be an “underwriter”
within the meaning of the Securities Act and the
compensation of Dawson James will be deemed
to be underwriting commission or discount. We have also agreed to provide indemnification
and contribution to Dawson James with respect
to certain liabilities, including liabilities
under the Securities Act or the Securities Exchange
Act of 1934, as amended (the “Exchange Act”). This offering
pursuant to this prospectus supplement and the accompanying prospectus will
terminate upon the earlier of (a) the sale of our Common Stock
pursuant to this prospectus supplement and the accompanying prospectus having an aggregate sales
price of $11,702,826, or (b) the termination by
us or Dawson James of the Sales Agreement
pursuant to its terms. See the section entitled
“Plan of Distribution” for additional information
regarding Dawson James’compensation.

We
are a “smaller reporting company”
under the federal securities laws and, as
such, are subject to reduced public company disclosure
standards for this prospectus supplement and future
filings. See the section entitled
“Prospectus Summary—Implications of Be ing a Smal ler Report ing Company” for additional information.

As of the date of this prospectus supplement,
the aggregate market value
of our outstanding Common Stock held by non-affiliates
is $35,108,479.50, based on 23,405,653shares of outstanding Common Stock held
by non-affiliates as of December 1, 2025 and a
price per share of $1.50, the closing price of our Common
Stock as reported
on Nasdaq on November 19, 2025. Pursuant to General Instruction
I.B.6 of Form S-3, in no event will we offer
to sell, pursuant to the registration statement
of which this prospectus supplement forms a part,
securities in a public primary offering
with a value exceeding one-third of our public
float in any 12-month period so long as the aggregate market value of our outstanding
Common Stock held by non-affiliates
remains below $75 million.
During the prior 12-calendar-month
period that ends on, and includes, the date of this prospectus supplement, we have offered
no securities pursuant to General Instruction I.B.6 of Form